Potential role of TRIM3 as a novel tumour suppressor in endometrial cancer development

This study investigates the biological functions of Tripartite motif-containing 3 (TRIM3) in endometrial cancer (EC). The expression patterns of TRIM3 in EC using the UALCAN and Kaplan-Meier Plotter databases, and investigated the relationship with the progression of EC in patients. EC cell lines, Ishikawa and HEC-1A were transfected with a vector expressing TRIM3 after pre-treated with/without pifithrin-α (an inhibitor of p53). Subsequently, in vitro cell proliferation and apoptosis were evaluated. Overexpression of TRIM3 resulted in inhibition of cell viability and clone formation and induced G1 phase arrest in Ishikawa and HEC-1A cells. Additionally, after TRIM3 was overexpressed, cell apoptosis was increased, and higher levels of Bax and lower levels of B-cell lymphoma-2 (Bcl-2) were observed in cells. Furthermore, heightened levels of p53 and p21 proteins were observed in Ishikawa and HEC-1A cells overexpressing TRIM3. However, pifithrin-α could counteract the effects of TRIM3 overexpression on EC cells. These data indicate that TRIM3 exerts a tumor suppressor effect in EC by activating the p53/p21 pathway.

Endometrial cancer (EC); TRIM3; p53; Proliferation; Apoptosis

[1] Berek J, Matias-Guiu X, Creutzberg C, Fotopoulou C, Gaffney D, Kehoe S, et al. FIGO staging of endometrial cancer: 2023. International Journal of Gynecology & Obstetrics. 2023; 162: 383–394.

[2] Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. The Lancet. 2022; 399: 1412–1428.

[3] Emons G, Steiner E, Vordermark D, Uleer C, Paradies K, Tempfer C, et al. Endometrial cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry Number 032/034-OL, September 2022). Part 1 with recommendations on the epidemiology, screening, diagnosis and hereditary factors of endometrial cancer, geriatric assessment and supply structures. Geburtshilfe und Frauenheilkunde. 2023; 83: 919–962.

[4] Trojano G, Olivieri C, Tinelli R, Damiani GR, Pellegrino A, Cicinelli E. Conservative treatment in early stage endometrial cancer: a review. Acta BioMedica. 2019; 90: 405–410.

[5] Yen TT, Wang TL, Fader AN, Shih IM, Gaillard S. Molecular classification and emerging targeted therapy in endometrial cancer. International Journal of Gynecological Pathology. 2020; 39: 26–35.

[6] Hatakeyama S. TRIM family proteins: roles in autophagy, immunity, and carcinogenesis. Trends in Biochemical Sciences. 2017; 42: 297–311.

[7] Zhao G, Liu C, Wen X, Luan G, Xie L, Guo X. The translational values of TRIM family in pan-cancers: from functions and mechanisms to clinics. Pharmacology & Therapeutics. 2021; 227: 107881.

[8] Lee HJ. The role of tripartite motif family proteins in TGF-β signaling pathway and cancer. Journal of Cancer Prevention. 2018; 23: 162–169.

[9] Zhuang T, Wang B, Tan X, Wu L, Li X, Li Z, et al. TRIM3 facilitates estrogen signaling and modulates breast cancer cell progression. Cell Communication and Signaling. 2022; 20: 45.

[10] Huang XQ, Zhang XF, Xia JH, Chao J, Pan QZ, Zhao JJ, et al. Tripartite motif-containing 3 (TRIM3) inhibits tumor growth and metastasis of liver cancer. Chinese Journal of Cancer. 2017; 36: 77.

[11] Zuo Q, Xu Q, Li Z, Luo D, Peng H, Duan Z. TRIM3 inhibits colorectal cancer cell migration and lipid droplet formation by promoting FABP4 degradation. Histology & Histopathology. 2024; 39: 239–250.

[12] Song Y, Guo Q, Gao S, Hua K. miR-454-3p promotes proliferation and induces apoptosis in human cervical cancer cells by targeting TRIM3. Biochemical and Biophysical Research Communications. 2019; 516: 872–879.

[13] Hong B, van den Heuvel AP, Prabhu VV, Zhang S, El-Deiry WS. Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities. Current Drug Targets. 2014; 15: 80–89.

[14] Thiel KW, Devor EJ, Filiaci VL, Mutch D, Moxley K, Alvarez Secord A, et al. TP53 sequencing and p53 immunohistochemistry predict outcomes when bevacizumab is added to frontline chemotherapy in endometrial cancer: an NRG oncology/gynecologic oncology group study. Journal of Clinical Oncology. 2022; 40: 3289–3300.

[15] Köbel M, Ronnett BM, Singh N, Soslow RA, Gilks CB, McCluggage WG. Interpretation of P53 immunohistochemistry in endometrial carcinomas: toward increased reproducibility. International Journal of Gynecological Pathology. 2019; 38: S123–S131.

[16] Costa BP, Nassr MT, Diz FM, Fernandes KHA, Antunes GL, Grun LK, et al. Methoxyeugenol regulates the p53/p21 pathway and suppresses human endometrial cancer cell proliferation. Journal of Ethnopharmacology. 2021; 267: 113645.

[17] Li LH, Zhang PR, Cai PY, Li ZC. Histone deacetylase inhibitor, Romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway. Biomedicine & Pharmacotherapy. 2016; 82: 161–166.

[18] Piao MY, Cao HL, He NN, Xu MQ, Dong WX, Wang WQ, et al. Potential role of TRIM3 as a novel tumour suppressor in colorectal cancer (CRC) development. Scandinavian Journal of Gastroenterology. 2016; 51: 572–582.

[19] Chen X, Li Q, Xie B, Ji Y, Han Y, Zhao Y. SNORA73B promotes endometrial cancer progression through targeting MIB1 and regulating host gene RCC1 alternative splicing. Journal of Cellular and Molecular Medicine. 2023; 27: 2890–2905.

[20] Song Y, Guo Q, Gao S, Hua K. Tripartite motif-containing protein 3 plays a role of tumor inhibitor in cervical cancer. Biochemical and Biophysical Research Communications. 2018; 498: 686–692.

[21] Farhadi J, Goshayeshi L, Motavalizadehkakhky A, Mehrzad J, Mehrad-Majd H. Decreased expression of TRIM3 gene predicts a poor prognosis in gastric cancer. Journal of Gastrointestinal Cancer. 2022; 53: 179–186.

[22] Zhang C, Liu J, Xu D, Zhang T, Hu W, Feng Z. Gain-of-function mutant p53 in cancer progression and therapy. Journal of Molecular Cell Biology. 2020; 12: 674–687.

[23] Mantovani F, Collavin L, Del Sal G. Mutant p53 as a guardian of the cancer cell. Cell Death & Differentiation. 2019; 26: 199–212.

[24] Donehower LA, Soussi T, Korkut A, Liu Y, Schultz A, Cardenas M, et al. Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas. Cell Reports. 2019; 28:1370–1384.e5.

[25] Halim F, Azhar Y, Suwarman S, Hernowo B. p53 mutation as plausible predictor for endocrine resistance therapy in luminal breast cancer. F1000Research. 2022; 11: 330.

[26] Baslan T, Morris JPt, Zhao Z, Reyes J, Ho YJ, Tsanov KM, et al. Ordered and deterministic cancer genome evolution after p53 loss. Nature. 2022; 608: 795–802.

[27] Vaddavalli PL, Schumacher B. The p53 network: cellular and systemic DNA damage responses in cancer and aging. Trend in Genetics. 2022; 38: 598–612.

[28] Chen X, Zhang T, Su W, Dou Z, Zhao D, Jin X, et al. Mutant p53 in cancer: from molecular mechanism to therapeutic modulation. Cell Death & Disease. 2022; 13: 974.

[29] Engeland K. Cell cycle regulation: p53-p21-RB signaling. Cell Death & Differentiation. 2022; 29: 946–960.

[30] Luo D, Yu C, Yu J, Su C, Li S, Liang P. p53-mediated G1 arrest requires the induction of both p21 and Killin in human colon cancer cells. Cell Cycle. 2022; 21: 140–151.

[31] Tran TQ, Lowman XH, Reid MA, Mendez-Dorantes C, Pan M, Yang Y, et al. Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction. Oncogene. 2017; 36: 1991–2001.

[32] Wang X, Zhang Y, Pei X, Guo G, Xue B, Duan X, et al. TRIM3 inhibits P53 signaling in breast cancer cells. Cancer Cell International. 2020; 20: 559.

[33] Deng Y, Shi Y, Wen C. TRIM3 inhibits H2O2-induced apoptosis in human lens epithelial cells by decreasing p53 via ubiquitination. Current Eye Research. 2022; 47: 747–752.